GB8504099D0
(en)
|
1985-02-18 |
1985-03-20 |
Wellcome Found |
Physiologically active substances
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
GB8610551D0
(en)
|
1986-04-30 |
1986-06-04 |
Hoffmann La Roche |
Polypeptide & protein derivatives
|
JPH0665280B2
(ja)
|
1987-03-04 |
1994-08-24 |
味の素株式会社 |
タンパクゲル化剤及びそれを用いるタンパクのゲル化方法
|
ATE198353T1
(de)
|
1988-08-24 |
2001-01-15 |
American Cyanamid Co |
Stabilisierung von somatotropinen durch modifikation von cystein-resten durch orts- spezifische mutagenese oder chemische derivatisierung
|
ATE189526T1
(de)
|
1988-10-28 |
2000-02-15 |
Genentech Inc |
Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
US5534617A
(en)
|
1988-10-28 |
1996-07-09 |
Genentech, Inc. |
Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
|
US5750373A
(en)
|
1990-12-03 |
1998-05-12 |
Genentech, Inc. |
Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
|
WO1990011296A1
(en)
|
1989-03-20 |
1990-10-04 |
The General Hospital Corporation |
Insulinotropic hormone
|
US5101018A
(en)
|
1989-06-12 |
1992-03-31 |
International Minerals & Chemical Corp. |
Method for recovering recombinant proteins
|
DE3930696A1
(de)
|
1989-09-14 |
1991-03-28 |
Hoechst Ag |
Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
|
CA2073856C
(en)
|
1990-01-24 |
2002-12-03 |
Douglas I. Buckley |
Glp-1 analogs useful for diabetes treatment
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
US5951972A
(en)
|
1990-05-04 |
1999-09-14 |
American Cyanamid Company |
Stabilization of somatotropins and other proteins by modification of cysteine residues
|
JP2849773B2
(ja)
|
1990-08-27 |
1999-01-27 |
天野製薬株式会社 |
ストレプトミセス属由来のトランスグルタミナーゼの製造法
|
DK220890D0
(da)
|
1990-09-14 |
1990-09-14 |
Ole Buchardt |
Fremgangsmaade til fremstilling af c-terminalt amiderede peptider
|
JP3267293B2
(ja)
|
1990-12-03 |
2002-03-18 |
ジェネンテク,インコーポレイテッド |
改変された結合性を有する変異タンパク質の豊富化法
|
IT1251895B
(it)
*
|
1991-09-27 |
1995-05-26 |
Eniricerche Spa |
Mutanti dell'ormone della crescita umano e loro impiego
|
DE69333718T2
(de)
|
1992-01-14 |
2005-12-01 |
Ajinomoto Co., Inc. |
Gen, das für eine Fisch-Transglutaminase kodiert
|
CA2489978A1
(en)
|
1992-07-31 |
1994-02-17 |
Genentech, Inc. |
Human growth hormone aqueous formulation
|
ZA936811B
(en)
|
1992-10-28 |
1995-03-15 |
Upjohn Co |
Somatotropin modifications
|
US5359030A
(en)
|
1993-05-10 |
1994-10-25 |
Protein Delivery, Inc. |
Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
|
DE69533606T2
(de)
|
1994-01-28 |
2006-03-02 |
Ajinomoto Co., Inc. |
Transglutaminase aus japanischer auster
|
ES2267103T3
(es)
|
1994-08-26 |
2007-03-01 |
Novozymes A/S |
Transglutaminasas microbianas, su produccion y uso.
|
US6010871A
(en)
|
1994-09-29 |
2000-01-04 |
Ajinomoto Co., Inc. |
Modification of peptide and protein
|
DE4437604A1
(de)
|
1994-10-21 |
1996-04-25 |
Basf Ag |
Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
|
CA2208730A1
(en)
|
1995-01-19 |
1996-07-25 |
Novo Nordisk A/S |
Transglutaminases from oomycetes
|
JP3669390B2
(ja)
|
1995-02-09 |
2005-07-06 |
味の素株式会社 |
バチルス属細菌由来のトランスグルタミナーゼ
|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
CA2658039A1
(en)
|
1995-09-21 |
1997-03-27 |
Genentech, Inc. |
Human growth hormone variants
|
US20020077461A1
(en)
|
1996-04-24 |
2002-06-20 |
Soren Bjorn |
Pharmaceutical formulation
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
JP2000517308A
(ja)
|
1996-08-30 |
2000-12-26 |
ノボ ノルディスク アクティーゼルスカブ |
Glp―2誘導体
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
BRPI9711437B8
(pt)
|
1996-08-30 |
2021-05-25 |
Novo Nordisk As |
derivados de glp-1
|
CN1231675A
(zh)
|
1996-09-26 |
1999-10-13 |
味之素株式会社 |
修饰的生理活性蛋白及含有该蛋白的药物组合物
|
US5985627A
(en)
|
1997-02-28 |
1999-11-16 |
Carlsberg Laboratory |
Modified carboxypeptidase
|
JPH1156378A
(ja)
|
1997-06-11 |
1999-03-02 |
Nippon Chem Res Kk |
変異型ヒト成長ホルモンとその用途
|
CN100404551C
(zh)
|
1997-06-25 |
2008-07-23 |
雪兰诺实验室有限公司 |
二硫键交联的糖蛋白激素类似物及其制备和应用
|
US7306931B2
(en)
*
|
2000-05-16 |
2007-12-11 |
Bolder Biotechnology, Inc. |
Method for refolding proteins containing free cysteine residues
|
DE69838552T2
(de)
|
1997-07-14 |
2008-05-21 |
Bolder Biotechnology, Inc., Louisville |
Derivate des wachstumshormons und verwandte proteine
|
JPH1192499A
(ja)
*
|
1997-09-22 |
1999-04-06 |
Sumitomo Pharmaceut Co Ltd |
ヒト成長ホルモン変異体
|
US6136536A
(en)
|
1997-10-29 |
2000-10-24 |
Genetics Institute, Inc. |
Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
|
EP1062240B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
N-terminally modified glp-1 derivatives
|
JP2002504518A
(ja)
|
1998-02-27 |
2002-02-12 |
ノボ ノルディスク アクティーゼルスカブ |
部分的に構造化されたミセルー様凝集体を形成する、25%を超えるヘリックス−含有率を有するglp−1誘導体
|
EP1056774A1
(en)
|
1998-02-27 |
2000-12-06 |
Novo Nordisk A/S |
N-terminally truncated glp-1 derivatives
|
JP2002504527A
(ja)
|
1998-02-27 |
2002-02-12 |
ノボ ノルディスク アクティーゼルスカブ |
部分的に組織化したミセル様凝集物を形成する25%を越えるヘリックス成分を有するglp−2誘導体
|
EP1056775B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
US6656922B2
(en)
|
1998-05-28 |
2003-12-02 |
Mediplex Corporation, Korea |
Oral delivery of macromolecules
|
US6358705B1
(en)
|
1998-07-16 |
2002-03-19 |
Novo Nordisk A/S |
Method of making proteins in transformed yeast cells
|
KR100452417B1
(ko)
|
1998-12-07 |
2004-10-12 |
소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. |
Glp-1의 유사체
|
US6329336B1
(en)
|
1999-05-17 |
2001-12-11 |
Conjuchem, Inc. |
Long lasting insulinotropic peptides
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
AU5805500A
(en)
|
1999-07-07 |
2001-01-30 |
Maxygen Aps |
A method for preparing modified polypeptides
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
GB2355009A
(en)
|
1999-07-30 |
2001-04-11 |
Univ Glasgow |
Peptides conjugated to bile acids/salts
|
US20040001827A1
(en)
|
2002-06-28 |
2004-01-01 |
Dennis Mark S. |
Serum albumin binding peptides for tumor targeting
|
JP2003519664A
(ja)
|
2000-01-11 |
2003-06-24 |
ノボ ノルディスク アクティーゼルスカブ |
Glp−1誘導体の経上皮送達
|
CN100488562C
(zh)
|
2000-02-11 |
2009-05-20 |
拜耳医药保健有限公司 |
凝血因子VⅡ或VⅡa样分子
|
JP2003530839A
(ja)
|
2000-04-12 |
2003-10-21 |
プリンシピア ファーマスーティカル コーポレイション |
アルブミン融合タンパク質
|
US20020142964A1
(en)
|
2000-11-02 |
2002-10-03 |
Nissen Torben Lauesgaard |
Single-chain polypeptides
|
DK1724284T3
(da)
|
2000-12-07 |
2009-11-02 |
Lilly Co Eli |
GLP-1 fusionsproteiner
|
US20060183197A1
(en)
|
2001-01-11 |
2006-08-17 |
Andersen Kim V |
Variant growth hormone molecules conjugated with macromolecules compounds
|
JP2004524020A
(ja)
*
|
2001-01-11 |
2004-08-12 |
マキシゲン・エイピーエス |
改良された成長ホルモン分子
|
FR2819810B1
(fr)
|
2001-01-23 |
2004-05-28 |
Pf Medicament |
Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
|
US6858580B2
(en)
|
2001-06-04 |
2005-02-22 |
Nobex Corporation |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
CA2450732A1
(en)
|
2001-06-14 |
2002-12-27 |
John H. Griffin |
Stabilized proteins with engineered disulfide bonds
|
DK1412384T3
(da)
|
2001-06-28 |
2008-04-28 |
Novo Nordisk As |
Stabil formulering af modificeret GLP-1
|
JP2004537580A
(ja)
|
2001-08-10 |
2004-12-16 |
エピックス メディカル, インコーポレイテッド |
延長された循環半減期を有するポリペプチド結合体
|
AR036711A1
(es)
|
2001-10-05 |
2004-09-29 |
Bayer Corp |
Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
|
AU2002341215A1
(en)
|
2001-11-12 |
2003-05-26 |
University Of Wales College Of Medicine |
Growth hormone variations in humans and their uses
|
HUP0500997A2
(en)
|
2001-11-20 |
2007-11-28 |
Pharmacia Corp |
Chemically-modified human growth hormone conjugates
|
JP2003199569A
(ja)
|
2001-12-17 |
2003-07-15 |
Food Industry Research & Development Inst |
ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ
|
FR2836382B1
(fr)
|
2002-02-28 |
2004-08-13 |
Biomerieux Sa |
Nouveaux agents de couplages, leurs conjugues, ainsi que l'utilisation de ces conjugues dans des methodes de diagnostic
|
US20050100963A1
(en)
|
2002-03-01 |
2005-05-12 |
Dyax Corporation |
KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
|
PL373658A1
(en)
|
2002-04-10 |
2005-09-05 |
Eli Lilly And Company |
Treatment of gastroparesis
|
US7700733B2
(en)
|
2002-04-30 |
2010-04-20 |
Bayer Healthcare Llc |
Factor VII or VIIa polypeptide variants
|
ES2343518T3
(es)
|
2002-09-09 |
2010-08-03 |
Hanall Biopharma Co., Ltd. |
Polipeptidos interferon alfa modificados resistentes a proteasas.
|
WO2004074315A2
(en)
|
2003-02-19 |
2004-09-02 |
Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) |
Analogues of glp-1
|
WO2004099246A2
(en)
|
2003-05-09 |
2004-11-18 |
Novo Nordisk A/S |
Peptides for use in treating obesity
|
JP2007501812A
(ja)
|
2003-08-08 |
2007-02-01 |
ノボ ノルディスク アクティーゼルスカブ |
ペプチドのための結合剤として新しい構造上十分に定義された枝分れしたポリマーの合成および適用
|
RU2401276C2
(ru)
|
2003-09-19 |
2010-10-10 |
Ново Нордиск А/С |
Производные глюкагон-подобного пептида-1 (glp-1)
|
EP1670515A2
(en)
|
2003-09-19 |
2006-06-21 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
CN100444898C
(zh)
|
2003-09-19 |
2008-12-24 |
诺沃挪第克公司 |
治疗肽的清蛋白结合型衍生物
|
TW200522976A
(en)
|
2003-09-19 |
2005-07-16 |
Novo Nordisk As |
Novel plasma protein affinity tags
|
EP1673464A2
(en)
|
2003-10-10 |
2006-06-28 |
Novo Nordisk A/S |
Conjugation of peptides
|
EP1704165B1
(en)
|
2003-12-18 |
2010-03-17 |
Novo Nordisk A/S |
Glp-1 compounds
|
CN101665538A
(zh)
|
2003-12-18 |
2010-03-10 |
诺沃挪第克公司 |
与白蛋白样物质相连的新glp-1类似物
|
ES2397241T3
(es)
|
2004-01-21 |
2013-03-05 |
Novo Nordisk Health Care Ag |
Conjugación de péptidos mediante transglutaminasa
|
JP4896745B2
(ja)
|
2004-02-02 |
2012-03-14 |
アンブレツクス・インコーポレイテツド |
修飾されたヒトインターフェロンポリペプチドおよびこれらの使用
|
CA2559918A1
(en)
|
2004-04-07 |
2005-11-10 |
Tudor Arvinte |
Liquid growth hormone formulation
|
US7906137B2
(en)
|
2004-05-21 |
2011-03-15 |
Mediplex Corporation, Korea |
Delivery agents for enhancing mucosal absorption of therapeutic agents
|
KR20070029247A
(ko)
|
2004-07-08 |
2007-03-13 |
노보 노르디스크 에이/에스 |
폴리펩티드 연장 태그
|
JP2008507990A
(ja)
|
2004-08-02 |
2008-03-21 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
Fviiの抱合体
|
US7893017B2
(en)
|
2004-10-07 |
2011-02-22 |
Novo Nordisk A/S |
Protracted GLP-1 compounds
|
US7998930B2
(en)
*
|
2004-11-04 |
2011-08-16 |
Hanall Biopharma Co., Ltd. |
Modified growth hormones
|
US7816320B2
(en)
|
2004-12-22 |
2010-10-19 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
|
KR20070120112A
(ko)
|
2005-03-18 |
2007-12-21 |
노보 노르디스크 에이/에스 |
연장형 glp-1 화합물
|
TWI372629B
(en)
|
2005-03-18 |
2012-09-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
US20090062192A1
(en)
|
2005-03-18 |
2009-03-05 |
Novo Nordisk A/S |
Dimeric Peptide Agonists of the Glp-1 Receptor
|
EP2360170A3
(en)
|
2005-06-17 |
2012-03-28 |
Novo Nordisk Health Care AG |
Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine
|
EP1919946A1
(en)
|
2005-08-18 |
2008-05-14 |
Novo Nordisk Health Care AG |
Transglutaminase variants with improved specificity
|
EP1928906A2
(en)
|
2005-08-30 |
2008-06-11 |
Novo Nordisk Health Care AG |
Liquid formulations of pegylated growth hormone
|
CN1939534B
(zh)
|
2005-09-27 |
2010-12-01 |
长春金赛药业股份有限公司 |
含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
|
CA2636797A1
(en)
*
|
2006-01-19 |
2007-08-23 |
Ambrx, Inc. |
Non-natural amino acid polypeptides having modulated immunogenicity
|
EP1986694B1
(en)
|
2006-02-14 |
2015-06-10 |
Novo Nordisk Health Care AG |
Coupling of polypeptides at the c-terminus
|
EP2040757A2
(en)
|
2006-07-07 |
2009-04-01 |
Novo Nordisk Health Care AG |
New protein conjugates and methods for their preparation
|
CA2672267C
(en)
|
2006-07-27 |
2016-05-31 |
Emisphere Technologies, Inc. |
Arylsulfanyl compounds and compositions for delivering active agents
|
EP2054435A1
(en)
|
2006-08-18 |
2009-05-06 |
Novo Nordisk Health Care AG |
Transglutaminase variants with improved specificity
|
EP2059260B1
(en)
|
2006-08-31 |
2013-06-19 |
Novartis AG |
Pharmaceutical compositions comprising hGH for oral delivery
|
US20080095837A1
(en)
|
2006-08-31 |
2008-04-24 |
Emisphere Technologies, Inc. |
Human growth hormone formulations
|
US8383852B2
(en)
|
2007-02-16 |
2013-02-26 |
Emisphere Technologies, Inc. |
Compounds having a cyclic moiety and compositions for delivering active agents
|
WO2008112836A2
(en)
|
2007-03-15 |
2008-09-18 |
Novartis Ag |
Pharmaceutical composition comprising human growth hormon
|
WO2009030771A1
(en)
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
MX2011000847A
(es)
|
2008-08-06 |
2011-02-25 |
Novo Nordisk Healthcare Ag |
Proteinas conjugadas con eficacia prolongada in vivo.
|
US20110263501A1
(en)
|
2008-09-09 |
2011-10-27 |
Nono Nordisk Health Care AG |
Growth Hormone Conjugate with Increased Stability
|
WO2010029159A1
(en)
|
2008-09-12 |
2010-03-18 |
Novo Nordisk A/S |
Method of acylating a peptide or protein
|
JP5816097B2
(ja)
|
2009-01-22 |
2015-11-18 |
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー |
安定な成長ホルモン化合物
|
WO2010102886A1
(en)
|
2009-02-19 |
2010-09-16 |
Novo Nordisk A/S |
Modification of factor viii
|
US8841249B2
(en)
|
2009-08-06 |
2014-09-23 |
Novo Nordisk A/S |
Growth hormones with prolonged in-vivo efficacy
|
EP2525834B1
(en)
|
2010-01-22 |
2019-07-17 |
Novo Nordisk Health Care AG |
Growth hormones with prolonged in-vivo efficacy
|
JP5980689B2
(ja)
|
2010-01-22 |
2016-08-31 |
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー |
安定な成長ホルモン化合物
|
ES2582590T3
(es)
|
2010-02-16 |
2016-09-13 |
Novo Nordisk A/S |
Método de purificación
|